Other

Merck Sharp + Dohme Corp.

N.v. Organon

Merck Sharp + Dohme B.v.

Msd Oss B.v.

Craig Jamieson

Jonathan Gillespie

John Kinnaird Ferguson MacLean

Zoran Rankovic

Elizabeth Margaret Moir

John Kinnaird Maclean

Simon James Anthony Grove

Ronald Palin

John Kinnaird Ferguson Maclean

Angus John Morrison

John K F MacLean

Kevin James Gillen

Amanda Jane Lyons

Michael Gerard Gallagher

John Kinaird Fergusen MaClean

Elizabeth M Moir

Kevin J Gillen

The invention relates to amino-heteroaryl derivatives having the general Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same, as well as to the use of these derivatives for the treatment of pain, such as neuropathic pain or inflammatory pain. 

Amino-heteroaryl derivatives as HCN blockers

The present invention relates to anindane derivative according to formula I wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising one or more of said indane derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and Alzheimer's disease. 

Indane derivatives

The present invention relates to a heterocyclic derivative according to formula (I); wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and Alzheimer's disease. 

Indane derivatives as AMPA receptor modulators

The present invention relates to a heterocyclic derivative according to formula I wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and learning and memory disorders such as Alzheimer's disease.

Substituted thieno[2,3-d]pyrimidines as AMPA modulators

The present invention relates to a heterocyclic derivative according to formula I wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising said heterocyclic derivatives and to their use in therapy, for instance in the treatment or prevention of psychiatric diseases where an enhancement of synaptic responses mediated by AMPA receptors is required, including schizophrenia, depression and Alzheimer's disease.

Heterocyclic derivatives

Growing community of inventors

Newhouse, United Kingdom

Craig Jamieson